Phase 3b open-label single group VDZ. Patients with CD. Induction and maintenance at standard doses.


<u>Primary endpoint</u>: Proportion of endoscopic remission w26. <u>Secondary endpoints</u>: endoscopic remission w14 and w52; radiologic response; complete mucosal healing; endoscopic response at w14,26 and 52; changes in SES-CD.

Results:

- Endoscopic remission: w26, 11.9% and w52, 17.9%.
- Remission in MRI: w26, 21.9% and w52,38.1%.
- Histologic response w26: 24.4% in the colon and 28.3% in the ileum.
- Histologic response w52: 20.5% colon and 34.3% ileum.

Conclusion:

Treatment with Vedolizumab in moderate-severe CD induces endoscopic, radiologic and histologic healing at 26 and 52w.



Week 14

Moderate (SES-CD 7 to 15) (n=29)

Week 14

Moderate (SES-CD

Week 26

Severe (SES-CD >15)



Severe (SES-CD >15)

Week 26